ATEC6342884 Bond Profile: Coupon and Redemption
This article provides a detailed profile of the Alphatec Holdings, Inc. bond ATEC6342884, with a 0.75% coupon rate maturing on March 15, 2030. It covers key facts about the issuer, bond classification, credit risk assessment, interest payment details, and a coupon payout schedule. The bond has an outstanding amount of 405.00 million USD and is a corporate bond issued by Alphatec Holdings, Inc., a company focused on spinal fusion technology.
ATEC Appoints Tommy Carls Executive Vice President, Data Intelligence and Strategy
Alphatec Holdings, Inc. (ATEC) has appointed Thomas “Tommy” Carls as Executive Vice President, Data Intelligence and Strategy. In this new role, Carls will lead ATEC's efforts across its EOSedge, EOS Insight, data acquisition and analytics, and the broader InformatiX strategy, aiming to integrate its procedural ecosystem and apply data and predictive analytics to enhance spine surgery. This appointment highlights ATEC's commitment to leveraging data for improved surgical outcomes and personalized patient care, building on Carls' three decades of experience in medical technology and spine.
2,520 shares of Alphatec Holdings (ATEC) are held directly by executive Carls Thomas Andrew.
Alphatec Holdings, Inc. executive Carls Thomas Andrew, EVP, Data & Imaging Solutions, reported direct ownership of 2,520 shares of common stock as of September 14, 2026. This information was filed with the SEC on September 24, 2026, as a Form 3, initial statement of beneficial ownership. The filing indicates a moderate impact and neutral sentiment.
Alphatec names Thomas Carls to lead data intelligence unit
Alphatec Holdings, Inc. has appointed Thomas Carls as Executive Vice President, Data Intelligence and Strategy. Carls, with over 30 years of experience in spine and medical technology, will be responsible for developing and marketing the company's data-driven products and strategies, including EOSedge and InformatiX. This strategic hire aims to enhance Alphatec's procedural ecosystem in spine surgery.
Alphatec Holdings, Inc. Announces Appointment of Thomas "Tommy" Carls as Executive Vice President, Data Intelligence and Strategy
Alphatec Holdings, Inc. has appointed Thomas "Tommy" Carls as Executive Vice President, Data Intelligence and Strategy. In this new role, Carls will lead the company's efforts in data acquisition, analytics, and the broader InformatiX strategy, reporting directly to the CEO. His focus will be on integrating data and predictive analytics across ATEC's procedural ecosystem to enhance surgical insights and improve spine care.
Alphatec (ATEC) Moves 19.7% Higher: Will This Strength Last?
Alphatec (ATEC) shares jumped 19.7% following strong Q2 2026 performance, with earnings of 7 cents per share and revenues of $213.5 million. The company maintains its full-year 2026 revenue guidance of approximately $882 million due to solid case volume growth and surgeon adoption. Despite the recent surge, the stock, currently holding a Zacks Rank #3 (Hold), faces uncertainty as its consensus EPS estimate for the upcoming quarter has remained unchanged, suggesting that continued strength might depend on future earnings estimate revisions.
What Is Driving Attention Around Alphatec Holdings (ATEC)?
Alphatec Holdings (ATEC) recently saw increased market attention due to a firm advance in its stock, renewing focus on its spine-surgery technology business. The company's market activity was directly linked to its healthcare profile, separating its performance from the broader market rebound. This interest was further supported by easing energy concerns and inflation updates that met expectations in the wider US equities market.
Alphatec Holdings CEO Patrick Miles buys $1.01m in common stock
Alphatec Holdings CEO Patrick Miles recently purchased 115,000 shares of the company's common stock for approximately $1.01 million, with the stock currently trading near its 52-week low and identified as undervalued by InvestingPro. This insider purchase follows a 15% increase in Alphatec's second-quarter revenue and an optimistic adjusted EBITDA, although the company was not profitable over the last year. Analysts predict profitability this year, and the company has raised its full-year earnings outlook.
Alphatec Holdings CEO Patrick Miles buys $1.01m in common stock
Alphatec Holdings CEO Patrick Miles recently purchased 115,000 shares of the company's common stock for approximately $1.01 million, at a weighted average price of $8.81 per share. This insider buying occurred while the stock was trading near its 52-week low and after a significant year-to-date decline. Analysts predict profitability for Alphatec Holdings this year, and the company recently reported a 15% increase in second-quarter revenue and a positive adjusted EBITDA.
Trading Systems Reacting to (ATEC) Volatility
This article analyzes Alphatec Holdings Inc. (NASDAQ: ATEC) volatility, indicating weak sentiment across all time horizons which supports a short bias. It outlines institutional trading strategies including a position trading strategy, a momentum breakout strategy, and a risk hedging strategy, each with specific entry, target, and stop-loss levels. The analysis emphasizes a high risk-reward short setup with a 30.7% downside target.
Spinal Stenosis Treatment Market Report Provides Insights Into Market Evolution And Growth Prospects
The spinal stenosis treatment market is projected to reach $12.77 billion by 2030, growing at a CAGR of 3.7%, driven by advancements in interventional pain therapies, personalized protocols, and tele-rehabilitation. Key players like Johnson & Johnson and Medtronic are making impacts, with strategic acquisitions like Stryker's purchase of Vertos Medical strengthening market positions. Technological advancements, particularly robotic-assisted minimally invasive surgeries, are enhancing treatment accuracy and patient recovery.
Spondylolisthesis Market Research Reveals Path To $23.71 Billion By 2030
The spondylolisthesis market is projected to reach $23.71 billion by 2030, growing at a CAGR of 5.4%, driven by technological advancements, personalized treatments, and an aging population. Key trends include early diagnosis, minimally invasive techniques, and better imaging. Prominent companies like Johnson & Johnson and Medtronic are leading innovations, such as Premia Spine's FDA-approved TOPS System, which offers a motion-preserving alternative to spinal fusion.
Alphatec Holdings, Inc. (NASDAQ:ATEC) Receives Average Recommendation of "Moderate Buy" from Brokerages
Alphatec Holdings, Inc. (NASDAQ:ATEC) has received an average rating of "Moderate Buy" from brokerages, with 13 buy ratings, one hold, and one sell. The company's average 12-month price target is $17.40, despite several firms recently lowering their targets. Alphatec reported strong quarterly earnings, matching estimates with $0.07 per share and exceeding revenue expectations with a 15.1% year-over-year increase to $213.51 million.
(ATEC) as a Liquidity Pulse for Institutional Tactics
This article provides an in-depth analysis of Alphatec Holdings Inc. (NASDAQ: ATEC), highlighting strong near and mid-term sentiment despite a weak long-term outlook. It details various institutional trading strategies, including position trading, momentum breakout, and risk hedging, based on AI-generated signals. The analysis also includes multi-timeframe signal strengths and key support/resistance levels for ATEC.
Why Alphatec Holdings (ATEC) Is Up 5.9% After Reaffirming 2026 Outlook And Narrowing Q2 Losses
Alphatec Holdings (ATEC) saw its stock rise 5.9% after reporting narrowed Q2 net losses and reaffirming its 2026 revenue guidance of approximately US$882 million. The company also filed a shelf registration for 800,000 common shares. This performance highlights Alphatec's cost discipline and continued investment in growth initiatives, reinforcing its path towards potential sustained profitability despite ongoing competition.
Why Alphatec Holdings (ATEC) Is Up 5.9% After Reaffirming 2026 Outlook And Narrowing Q2 Losses
Alphatec Holdings (ATEC) saw its stock rise by 5.9% after announcing Q2 results that showed a narrowed net loss and reaffirmed its 2026 revenue guidance of approximately US$882 million. The company also filed an US$8.12 million shelf registration related to an ESOP offering. This positive movement is attributed to management's continued focus on cost discipline and growth initiatives, reinforcing the company's investment narrative of achieving sustained profitability through its spine portfolio and EOS ecosystem.
HC Wainwright Analysts Raise Earnings Estimates for Alphatec
HC Wainwright analysts have raised their Q3 2026 EPS estimate for Alphatec (NASDAQ:ATEC) to a loss of $0.02 from $0.06, maintaining a "Buy" rating and a $24 price target. The firm anticipates Alphatec will achieve positive quarterly earnings in 2027, projecting EPS between $0.08 and $0.18, and further growth to $0.79 in 2028 and $1.05 in 2029. Despite a recent strong revenue report, the company remains unprofitable overall, with a consensus "Moderate Buy" rating from analysts and an average price target of $17.40.
ATEC Stock Price and Chart — NASDAQ:ATEC
This article provides a detailed overview of Alphatec Holdings, Inc. (NASDAQ:ATEC) stock, including its current price, historical performance, key financial metrics, and analyst ratings. It highlights the company's focus on spinal fusion technology and reports its Q2 2026 earnings, showing revenue growth and increased adjusted EBITDA. The article also includes various trading ideas and technical analyses for ATEC.
HC Wainwright Cuts Earnings Estimates for Alphatec
HC Wainwright has reduced its FY2027 earnings per share (EPS) estimate for Alphatec to $0.47 from $0.59, while reiterating a "Buy" rating and a $24 price target. This revision follows Alphatec's recent quarterly earnings which met EPS expectations of $0.07 and surpassed revenue forecasts with $213.51 million, marking a 15.1% year-over-year increase. Despite the lowered earnings forecast, analyst sentiment remains largely positive for the medical technology company.
Enterprise value to EBITDA forward of Alphatec Holdings, Inc. – DUS:L1Z1
This page from TradingView provides financial information for Alphatec Holdings, Inc. (L1Z1) on the Dusseldorf Stock Exchange, specifically focusing on its enterprise value to EBITDA forward metric. The content highlights financial data sourced from ICE Data Services, FactSet, and SEC filings from Quartr.
What Alphatec Holdings (ATEC)'s Reaffirmed 2026 Outlook and Narrowing Losses Mean For Shareholders
Alphatec Holdings (ATEC) recently reported Q2 and H1 2026 results, showing reduced net losses and reaffirming its full-year 2026 revenue guidance of approximately US$882 million. This positive outlook, driven by increasing surgeon adoption and procedural volumes, supports the company's path toward profitability despite ongoing operating losses. The reaffirmed guidance and narrowing losses are seen as a positive development for investors, though risks associated with cash burn and cost pressures remain.
Alphatec Holdings general counsel sells $78,821 in ATEC shares
Tyson Eliot Marshall, General Counsel of Alphatec Holdings (NASDAQ:ATEC), sold 8,168 shares for a total of $78,821 to cover tax withholding obligations from vested restricted stock units. This sale was conducted under a Rule 10b5-1 trading plan. Despite the stock being down 56% year-to-date, analysts predict a return to profitability for Alphatec Holdings this year, and the company recently reported increased Q2 revenue and adjusted EBITDA.
Insider Selling: Alphatec (NASDAQ:ATEC) General Counsel Sells 8,168 Shares
Alphatec (NASDAQ:ATEC) General Counsel Tyson Eliot Marshall sold 8,168 shares of the company's stock, valued at $78,821.20, on August 5th. This transaction was part of a pre-arranged Rule 10b5-1 plan to cover tax withholding obligations from vested equity awards. Despite this insider sale, Alphatec holds a "Moderate Buy" consensus rating from analysts with an average price target of $17.40, significantly higher than its current trading price of $9.31.
Alphatec Holdings, Inc. (NASDAQ:ATEC) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
This article discusses Alphatec Holdings' second-quarter earnings report and how analysts have reacted, including changes to their future earnings forecasts. It highlights the company's revenue and earnings per share, and provides an updated consensus view on the stock's future performance.
Alphatec Holdings, Inc. (NASDAQ:ATEC) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
Alphatec Holdings recently reported its second-quarter earnings, leading to analysts updating their price targets and earnings forecasts for the company. While sales beat expectations, earnings per share missed targets, resulting in a slight reduction in the consensus price target. The article examines the sentiment of analysts following these results and updates on Alphatec's financial performance and future outlook.
What Alphatec Holdings (ATEC)'s Reaffirmed 2026 Outlook and Narrowing Losses Mean For Shareholders
Alphatec Holdings (ATEC) has reported its Q2 and H1 2026 results, showing reduced net losses and reaffirming its full-year 2026 revenue guidance of approximately US$882 million. This positive outlook, driven by increasing surgeon adoption and procedural volumes, supports the company's investment narrative toward profitability despite ongoing losses and competitive pressures. Investors should consider how these improvements impact previous analyst expectations and the company's valuation.
ETFs Investing in Alphatec Holdings, Inc. Stocks
This article lists various ETFs that invest in Alphatec Holdings, Inc. (ATEC) stocks, providing details such as market value, weight, issuer, management style, focus, expense ratio, AUM, price, and performance metrics for each fund. The funds primarily target small-cap and healthcare sectors, indicating ATEC's presence within these investment strategies. The data helps potential investors identify ETFs that hold ATEC stocks, offering diversified investment opportunities.
Narrower Losses And Reaffirmed 2026 Revenue Guidance Might Change The Case For Investing In Alphatec Holdings (ATEC)
Alphatec Holdings (ATEC) reported narrower net losses in Q2 2026 and reaffirmed its full-year 2026 revenue guidance of approximately US$882 million. This consistent outlook, along with reduced losses, reinforces management's confidence in growth and surgical volume, but the company still faces risks related to ongoing high investment and competitive intensity affecting profitability. The article suggests these updates might shift the investment narrative and risk profile for ATEC, with some analysts potentially revising their more conservative forecasts.
Alphatec Holdings, Inc. $ATEC Shares Purchased by Renaissance Technologies LLC
Renaissance Technologies LLC significantly increased its stake in Alphatec Holdings, Inc. ($ATEC) by 21.3% in the first quarter of 2026, acquiring an additional 184,969 shares and bringing its total holdings to over 1 million shares. Other institutional investors also boosted their positions in the medical technology company. Analysts generally maintain a "Moderate Buy" rating for Alphatec with a consensus price target of $17.13, despite one firm lowering its target.
Alphatec Holdings (ATEC) Stock Sinks As Margin Gains Fail To Convince
Alphatec Holdings' stock (ATEC) dropped 7.5% despite reporting improved Q2 2026 results, including narrowed losses, increased revenue, and higher adjusted EBITDA with a 17% margin. While the company showed strong surgeon adoption and operating leverage, investors remain concerned about execution risks with new products and ongoing legal investigations, which are preventing them from seeing the improved financials as a permanent fix.
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Alphatec Holdings (ATEC), Amgen (AMGN) and Vertex Pharmaceuticals (VRTX)
The article provides an overview of recent analyst ratings for three healthcare stocks: Alphatec Holdings (ATEC), Amgen (AMGN), and Vertex Pharmaceuticals (VRTX). Alphatec Holdings received a Strong Buy consensus with significant upside potential. Amgen has a Moderate Buy consensus but with a slight downside from current levels, while Vertex Pharmaceuticals also has a Strong Buy consensus indicating substantial upside.
Alphatec Holdings Number of Employees 2026 | Employee Count & Headcount Data
Alphatec Holdings (NASDAQ: ATEC) has approximately 952 employees worldwide as of March 2026, representing a 14.2% growth since 2023. The company is actively hiring, with 68 active job postings in 2026, and its workforce is primarily concentrated in North America, with Finance and Operations being the largest functional group. The average salary at Alphatec Holdings is $109,339, though employee sentiment is currently negative and declining.
(ATEC) Risk Channels and Responsive Allocation
This article provides an AI-driven analysis of Alphatec Holdings Inc. (NASDAQ: ATEC), highlighting a strong near-to-mid-term sentiment but a weak long-term outlook. It identifies an exceptional 185.0:1 risk-reward setup targeting a 43.3% gain against a 0.2% risk and outlines specific position, momentum, and risk-hedging trading strategies for different risk profiles. The analysis emphasizes the prevailing positive sentiment and offers multi-timeframe signal analysis with support and resistance levels.
Alphatec Holdings, Inc. SEC Filing (Aug 5, 2026)
Alphatec Holdings, Inc. (ATEC) filed a Form 144 with the SEC on August 5, 2026, indicating a proposed sale of securities. The filing details the sale of 8,168 common shares with an aggregate market value of $84,538.80, acquired on the same date as Restricted Stock Units from the issuer. This notice is a standard disclosure for individuals intending to sell restricted or controlled securities.
UBS Adjusts Price Target on Alphatec Holdings to $16 From $15, Maintains Buy Rating
UBS has increased its price target for Alphatec Holdings (ATEC) to $16 from $15, while reaffirming a Buy rating on the stock. This adjustment reflects the analyst's updated outlook for the medical device company. Alphatec Holdings specializes in technology for spinal disorder treatment and has recently been the subject of several analyst recommendations.
Alphatec Holdings, Inc. Stock 12‑Month Price Target Raised to $16.07, Implies 55% Upside
Analysts have raised the 12-month price target for Alphatec Holdings, Inc. stock to $16.07, up from $15.86, with forecasts ranging from $12 to $24 per share. This new target suggests a potential upside of approximately 55% based on the August 4 closing price. The consensus rating for Alphatec Holdings, Inc. remains a "Buy" among all 14 covering analysts.
Alphatec earnings up next: Can spine disruptor ease growth fears?
Alphatec Holdings Inc. is scheduled to report second-quarter earnings, with investors closely watching whether the company's "proceduralization" strategy can sustain market-share gains amidst concerns about surgical revenue growth. Analysts expect 7 cents per share on revenue of $211.24 million, and while all 14 analysts rate the stock a buy, there are investor worries about potential guidance cuts and the ability of margin expansion to offset growth moderation. The report will be crucial in determining if recent downgrades are prescient or if the stock's significant decline presents an oversold opportunity.
Alphatec Q2 2026 Earnings Call Transcript
Alphatec reported strong Q2 2026 results, with revenue up 15% to $214 million and adjusted EBITDA up 53% to $36 million, driven by increased surgical adoption and procedural volume. The company generated positive free cash flow and raised its full-year adjusted EBITDA guidance to $140 million while maintaining revenue guidance of $882 million. Management emphasized the success of their procedural-based approach, the strategic value of EOS and EOS Insight in driving surgeon engagement, and their continued focus on clinical distinction and market expansion.
ATEC Q2 2026 slides: profitability growth outpaces revenue gains
Alphatec Holdings Inc. (ATEC) reported strong Q2 2026 financial results, with adjusted EBITDA surging 53% to $36 million on 15% revenue growth to $214 million, significantly outpacing Wall Street expectations for revenue. Despite strong operational performance and increased profitability, the stock declined 2.96% after hours due to investor concerns about a 2.7% decline in revenue per case and flat EOS imaging revenue. The company affirmed its full-year 2026 revenue guidance of $882 million while raising adjusted EBITDA expectations to $140 million, highlighting its focus on clinical distinction and an integrated procedural ecosystem.
Alphatec Holdings (NASDAQ:ATEC) Shares Dip Slightly After In-Line Q2 Results
Alphatec Holdings (NASDAQ:ATEC) reported Q2 2026 revenue of $213.5 million and non-GAAP EPS of $0.07, aligning with analyst estimates. Despite in-line results and a 15% year-over-year revenue increase, shares experienced a slight dip after hours, likely due to full-year revenue guidance remaining below consensus. The company reaffirmed its full-year revenue outlook and raised its adjusted EBITDA guidance.
Alphatec Holdings (Nasdaq: ATEC) lifts 2026 EBITDA outlook after Q2
Alphatec Holdings (ATEC) reported strong Q2 2026 results, with total revenue up 15% year-over-year to $214 million and adjusted EBITDA reaching $36 million. The company reaffirmed its full-year 2026 revenue guidance of $882 million and raised its adjusted EBITDA outlook from $134 million to $140 million, while maintaining a target of at least $20 million in free cash flow. Despite continued GAAP net losses, Alphatec highlights significant growth in surgical revenue, margin expansion, and surgeon adoption, attributing success to its "Organic Innovation Machine" and focus on clinical distinction.
Alphatec earnings up next: Can spine disruptor ease growth fears? By Investing.com
Alphatec Holdings Inc. is set to report second-quarter earnings, with analysts keenly watching if its growth momentum can alleviate investor concerns about its surgical revenue trajectory. Despite all 14 analysts rating the stock a buy with a 56% implied upside, EPS estimates have slightly declined, signaling caution. Key areas of focus include the "proceduralization" strategy's ability to sustain market share gains, execution in the EOS imaging business, and whether margin expansion can offset any potential moderation in volume growth.
Earnings Flash (ATEC) Alphatec Holdings, Inc. Reports Q2 Revenue $213.5M, vs. FactSet Est of $211.3M
Alphatec Holdings, Inc. (ATEC) announced its Q2 revenue reached $213.5 million, surpassing the FactSet estimate of $211.3 million. The company reaffirmed its earnings guidance for the full-year 2026. This positive financial update follows several recent analyst initiations and price target adjustments for Alphatec Holdings.
Sei Investments Co. Buys 229,238 Shares of Alphatec Holdings, Inc. $ATEC
Sei Investments Co. significantly increased its stake in Alphatec Holdings, Inc. (NASDAQ:ATEC) during the first quarter, purchasing an additional 229,238 shares, bringing its total holdings to 598,003 shares valued at approximately $6.5 million. This move is part of broader institutional interest, with such investors owning 66.35% of Alphatec's stock. Despite a recent insider sale by a director, analysts maintain a "Moderate Buy" consensus for the medical technology company, with an average price target of $17.13.
Enterprise value to revenue forward of Alphatec Holdings, Inc. – NASDAQ:ATEC
This article focuses solely on the enterprise value to revenue forward for Alphatec Holdings, Inc. (NASDAQ: ATEC). The content appears to be a financial data point from TradingView, indicating a specific period's value, change, and percentage change for this metric. No additional financial analysis or details are provided beyond this isolated data point.
Alphatec Holdings, Inc. Revenue Breakdown – NASDAQ:ATEC
Alphatec Holdings, Inc. (NASDAQ: ATEC) generated $764.15 million in revenue last year, primarily from its Spinal Surgery Implants segment. This segment was also its top performer the previous year, contributing $611.56 million. The United States was the largest geographical contributor, accounting for $716.14 million of the revenue.
UBS Initiates Alphatec Holdings at Buy With $15 Price Target
UBS has initiated coverage on Alphatec Holdings (ATEC) with a Buy rating and a $15 price target. This initiation suggests a positive outlook from UBS on the company's future performance.
Alphatec Holdings, Inc. Revenue Breakdown – SWB:L1Z1
Alphatec Holdings, Inc. (SWB:L1Z1) generated €650.62 million in revenue last year, primarily from its Spinal Surgery Implants segment. The United States was the largest contributor to its revenue, accounting for €609.74 million. This represents an increase from the previous year's figures for both the segment and the region.
UBS Initiates Alphatec Holdings at Buy With $15 Price Target
UBS has initiated coverage on Alphatec Holdings (NASDAQ: ATEC) with a "Buy" rating and a price target of $15. This follows similar initiations from Stephens and BMO Capital with "Overweight" and "Outperform" ratings, respectively. The medical device company, focused on spinal disorder treatment, has seen several analyst actions recently, including Needham adjusting its price target to $14 while maintaining a "Buy" rating.
Alphatec Holdings Inc (ATEC) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Alphatec Holdings Inc (ATEC), detailing its price momentum, support and resistance levels, and the readings from various technical indicators and moving averages. As of the analysis, ATEC's price momentum score is 4.02 and the stock is trading between a resistance level of 9.74 and a support level of 7.81. While technical indicators show mixed signals, moving averages suggest a generally positive outlook.
